SCHEMBL2305598

SCHEMBL2305598

O=C(NCCOc1ccc2c(C3CC3)nn(Cc3ccccc3)c2c1)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
MAPT P10636 1/20 0.49
SLC22A12 Q96S37 1/20 0.45
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CSF1R P07333 1/20 0.42
CHRNA7 P36544 1/20 0.42
HTR3A P46098 2/20 0.41
BRD4 O60885 1/20 0.41
KAT2B Q92831 1/20 0.40
KLKB1 P03952 1/20 0.40
PDE1B Q01064 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PLA2G4A P47712 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
HTT P42858 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238106 0.83 L3MBTL1 (0.53) L3MBTL1MAPTSLC22A12LMNASMN1; SMN2
SCHEMBL1941016 0.79 CNR1 (0.46) SLC22A12HTR3A
SCHEMBL1940935 0.74 CA12 (0.44) SLC22A12
SCHEMBL177177 0.72 SLC22A12 (0.48) SLC22A12KLKB1MEN1KMT2A
SCHEMBL3811564 0.71 L3MBTL1 (0.80) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL30288328 0.71 L3MBTL1 (0.61) L3MBTL1MAPTLMNASMN1; SMN2MEN1
SCHEMBL2306802 0.70 SLC22A12 (0.50) SLC22A12CHRNA7
SCHEMBL7108541 0.70 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL7110432 0.70 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2HTT
SCHEMBL7109712 0.70 L3MBTL1 (0.60) L3MBTL1MAPTLMNASMN1; SMN2KAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304443-B2 Indazole derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2012-11-06 US disclosed
US-8304443-B2 Indazole derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2012-11-06 US disclosed
US-8304443-B2 Indazole derivatives ASAHI KASEI PHARMA CORPORATION (JP) 2012-11-06 US disclosed
EP-2351742-A1 INDAZOLE DERIVATIVE Asahi Kasei Pharma Corporation (JP) 2011-08-03 EP disclosed
US-20100152265-A1 INDAZOLE DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-17 US disclosed
US-20100152265-A1 INDAZOLE DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-17 US disclosed
US-20100152265-A1 INDAZOLE DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152265-A1 INDAZOLE DERIVATIVES ADRB3, INSR, ADRB1 L3MBTL1 2944/4885MAPT 748/4885SLC22A12 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.